New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.
TPIV200 stimulates T cells to attack ovarian and triple-negative breast tumor cells that over-express the folate receptor alpha protein.
A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.
The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A study presented at the SGO Annual Meeting found that PARP-7 amplification mutations are associated with prolonged survival among patients with platinum-sensitive ovarian cancer.